T-CURX GMBH

Their core work

T-CURX is a Würzburg-based biotech SME specialized in engineered T-cell therapies for cancer treatment, particularly CAR T-cell and TCR-based approaches. They develop genetically modified immune cells using technologies like the Sleeping Beauty transposon system to target hematologic malignancies such as multiple myeloma. Their work spans from preclinical development through GMP manufacturing considerations, including safety assessment and analytical monitoring of advanced therapy medicinal products (ATMPs). They contribute translational expertise to large European consortia working to bring cell-based immunotherapies from lab to clinic.

What they specialise in

How they've shifted over time

T-CURX entered H2020 with a tight focus on a specific CAR T-cell product — the CARAMBA project targeted SLAMF7-positive multiple myeloma using Sleeping Beauty-based gene transfer. Over subsequent projects, their scope broadened significantly: imSAVAR brought them into immune safety assessment, computational immunology, and micro-physiological systems for toxicology, while T2EVOLVE extended their reach to the full development pipeline including GMP manufacturing, regulatory frameworks, and patient involvement. The trajectory shows a company maturing from a single-product focus toward becoming a broader cell therapy platform contributor with growing interest in manufacturing and safety infrastructure.

T-CURX is moving from pure therapeutic development toward the enabling infrastructure of cell therapy — safety assessment, GMP processes, and regulatory readiness — positioning them for the commercialization phase of the ATMP field.

How they like to work

T-CURX operates exclusively as a participant, never coordinating, which is typical for a specialized SME contributing focused technical expertise to larger research efforts. With 58 unique partners across just 3 projects, they work in large consortia (averaging ~19 partners per project), indicating comfort operating within complex multi-partner structures. Their role pattern suggests they are brought in for specific T-cell engineering and development capabilities rather than driving overall project direction.

Despite only 3 projects, T-CURX has built a substantial network of 58 unique partners across 13 countries, reflecting their participation in major European health research consortia. Their geographic spread covers much of the EU, consistent with the large-scale collaborative nature of cell therapy research programs.

What sets them apart

T-CURX occupies a distinctive niche as a German SME bridging academic CAR T-cell research and industrial cell therapy development, rooted in the Würzburg research ecosystem known for its immunotherapy expertise. Their combination of hands-on genetic engineering capability (Sleeping Beauty transposon system) with growing experience in safety assessment and GMP manufacturing makes them a practical partner for consortia needing translational cell therapy expertise. For a small company, their breadth across the development chain — from construct design to preclinical safety to manufacturing — is uncommon and valuable.

Highlights from their portfolio

• CARAMBA
  Their largest-funded project (EUR 453,750), targeting multiple myeloma with an innovative non-viral Sleeping Beauty gene-transfer approach to CAR T-cell manufacturing — a potential cost-reducing alternative to viral vector methods.
• T2EVOLVE
  Addresses the full ecosystem challenge of CAR/TCR T-cell therapy access — from preclinical models through GMP manufacturing to patient involvement — signaling T-CURX's expansion beyond pure R&D.
• imSAVAR
  Represents a strategic diversification into immune safety and computational immunology, connecting T-CURX to the regulatory science side of immunotherapy development.